Pure redox-sensitive paclitaxel-maleimide prodrug nanoparticles: Endogenous albumin-induced size switching and improved antitumor efficiency

A commercial albumin-bound paclitaxel nano-formulation has been considered a gold standard against breast cancer. However, its application still restricted unfavorable pharmacokinetics and the immunogenicity of exogenous albumin carrier. Herein, we report an albumin-bound tumor redox-responsive paclitaxel prodrugs nano-delivery strategy. Using diverse linkages (thioether bond and disulfide bond), paclitaxel (PTX) was conjugated with an albumin-binding maleimide (MAL) functional group. These pure PTX prodrugs could self-assemble to form uniform and spherical nanoparticles (NPs) in aqueous solution without any excipients. By immediately binding to blood circulating albumin after intravenous administration, NPs are rapidly disintegrated into small prodrug/albumin nanoaggregates

Clinical efficacy and safety of abraxane in alternative chemotherapy plan of metastatic breast cancer / 中国综合临床

Objective To investigate the therapy effect and adverse reaction of the abraxane chemotherapy as a alternative plan in metastatic breast cancer.Methods Twenty-one patients with advanced metastatic breast cancer were selected as our subject.All the patients received rescue chemotherapy after relapse and metastasis.Abraxane were administrated with 260 mg/m2 3 weeks/time,and evaluated the effect in every two course of radiotherapy.Results Of 21 cases,4 cases were remission and 8 cases were with stable progress of cancer.No allergic reaction occurred.The majority adverse reaction were granulocytopenia and nerve toxicity.Conclusion Abraxane migh be considered as the altemate therapy medicine of metastatic breast cancer due to good curative effect,less toxicity reaction and no allergic reaction.